Drug intelligence / Profile preview

lactobacillus reuteri LR09

Development stage: Preclinical
Lead developer: Zhengzhou H&H Bioengineering
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus reuteri LR09 (also known as PB-LR09) is a specific strain of the probiotic bacterium Limosilactobacillus reuteri. It is being developed by Shanenkang Biotechnology (Suzhou) Co., Ltd. and has been studied for its potential therapeutic effects. A clinical trial investigated its use for the improvement of Helicobacter pylori infection. [7] The mechanism of action is thought to involve the production of antimicrobial substances, competition with pathogens for adhesion to the gut lining, and modulation of the host immune system. [6, 8] A patent also describes its use, along with Lactobacillus rhamnosus PB-LR76, in a formulation intended to improve vaginitis. [7] The strain was deposited in the China Center for Type Culture Collection with the accession number CCTCC NO: M2018888. [7]

Other names: 罗伊氏乳杆菌LR09

Beyond the preview

Go deeper on lactobacillus reuteri LR09.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus reuteri LR09.

Explore the full profile